International Multicenter Retrospective Study on UBTF-Related Neurodevelopmental Disorder
23 affiliations
- 1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Italy
- 2Child Neuropsychiatric Unit, Istituto G. Gaslini, Genoa, Italy
- 3Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
- 4Centro Epilessia, Azienda Ospedaliera Universitaria Federico II di Napoli, Naples, Italy
- 5Department of Precision Medicine, University “Luigi Vanvitelli”, Naples, Italy
- 6Division of Pediatric Neurology, Children's Medical Center, Taichung Veterans General Hospital, Taiwan
- 7Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan .
- 8Department of Neuropediatrics, University Children's Hospital, Klinikum Oldenburg, Germany
- 9Department Woman-Mother-Child, Unit of Paediatric Neurology and Neurorehabilitation, Lausanne University Hospital (CHUV), Switzerland
- 10Neurogenetic Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital, Prague, Czech Republic
- 11Department of Neurology, Massachusetts General Hospital, Boston
- 12Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
- 13Department of Genetics, Texas Children's Hospital, Houston
- 14Veracity Neuroscience LLC, Memphis, TN
- 15University of Memphis, TN
- 16Molecular Genetics and Functional Genomics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy .
- 17Center for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 18U.O. Genetica Medica, Azienda USL della Romagna, Ravenna, Italy
- 19Division of Pediatric Neurology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
- 20AHU Institut de génétique médicale, CHU de Lille, France
- 21Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 22IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Neuropsichiatria dell'età pediatrica, Bologna, Italy ; and
- 23Department of Medical Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
Background and Objectives: UBTF encodes the upstream binding transcription factor (UBTF), a protein essential for rRNA synthesis. Dominantly acting pathogenic variants, either de novo or inherited, have been associated with a broad clinical childhood-onset neurodegenerative/neurodevelopmental spectrum whose genotype-phenotype correlation has not been accurately defined yet. This multicenter study aims to conduct a retrospective analysis of a large cohort of patients with pathogenic variants in the UBTF gene to refine diagnostic criteria and identify clinically relevant outcome measures for future trials.
Methods: Clinical centers provided clinical, molecular, and neuroimaging data on patients carrying pathogenic or predicted pathogenic UBTF variants, consistent with the clinical phenotype. Data were collected using an human phenotype ontology–based standardized electronic case report form and included unreported cases or updated information on patients reported in the literature from January 2017 to December 2024.
Results: A cohort of 49 patients (23 previously unreported) was included in the study. The disease typically presented at ≤3 years (89.6%) with neuroregression in 71.4% of cases, either in a child with preexisting neurodevelopmental delay (42.9%) or after previously normal psychomotor development (28.6%). Less frequently, neurodevelopmental delay occurred in isolation (26.5%). During disease progression, patients developed behavioral abnormalities (81.6%), movement disorders (78.3%), autonomic manifestations (50.0%), and epilepsy (34.7%). At the last follow-up (mean age 13 years and 6 months), only 2 patients were deceased (4.1%). The main neuroimaging findings included white matter hyperintensity (68.1%), cerebral (66.0%) and cerebellar (51.1%) atrophy, and thinning of the corpus callosum (38.3%). However, brain MRI findings were reported as normal in 21.3% of cases. We identified 7 novel UBTF variants (c.271G>C; c.349A>T; c.495C>A; c.517G>A; c.761A>G; c.1048-2A>G; and c.1625_1626+15del). Genotype-phenotype analysis led to the distinction of 2 allelic, clinically distinct disorders: a childhood-onset neurodegenerative disease due to gain-of-function variants, characterized by the triad of neuroregression, movement, and behavioral disorders, and a neurodevelopmental disorder with a milder clinical course associated with loss-of-function/hypomorphic variants.
Discussion: The results from our deep-phenotyping analysis suggest the classification of UBTF-related disease into 2 main clinical syndromes impacting the natural history of the disease with a different degree of severity and complexity. This novel observation should be considered in the management and prognosis of patients and will be fundamental in the design of targeted therapies.
Related
- Myoclonus, Dystonia, and Ataxia in U2AF2 ‐Related Neurodevelopmental Disorder
- Neurobehavioral Profiles and Clinical Consequences of MYT1L-Related Neurodevelopmental Disorder: Insights from the Brain Gene Registry
- Characterization of the Grin1Q536R/+ mouse: a preclinical model for GRIN1-related neurodevelopmental disorder
- Chromodomain Helicase DNA-Binding Domain 8 (CHD8) related neurodevelopmental disorder with overgrowth: a case series and a systematic literature review on neuroradiological findings
- Motor, Postural, and Communicative Phenotype in SHQ1-Related Neurodevelopmental Disorder with Dystonia and Seizures: An Interdisciplinary Case Report and Hypothesis-Generating Physiotherapy Framework.
BibTeX
@article{balletto2026international,
title = {{International Multicenter Retrospective Study on UBTF-Related Neurodevelopmental Disorder}},
author = {Giulia Balletto and Sara Carli and Antonietta Coppola and Annalaura Torella and Hsiu-Fen Lee and Christoph Korenke and Sebastien Lebon and Lucie Sedlackova and Amanda Nagy and Florian S. Eichler and Chaya N. Murali and Vincenzo Nigro and Farah Alnoor Ladha and Mark S. Ledoux and Silvia Pelle and Giulia Prato and Lino Nobili and Luigi Chiriatti and Cecilia Mancini and Giuseppe Zampino and Claudio Graziano and Kristin Baranano and Pauline Planté-Bordeneuve and Roseline Caumes and Barbora Lauerová and Jana Haberlová and Duccio Maria Cordelli and Chiara Fiorillo and Marco Tartaglia and Rory James Tinker and Caterina Garone},
journal = {Neurology: Genetics},
year = {2026},
month = nov,
doi = {10.1212/nxg.0000000000200447},
url = {https://doi.org/10.1212/nxg.0000000000200447},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - International Multicenter Retrospective Study on UBTF-Related Neurodevelopmental Disorder
AU - Giulia Balletto
AU - Sara Carli
AU - Antonietta Coppola
AU - Annalaura Torella
AU - Hsiu-Fen Lee
AU - Christoph Korenke
AU - Sebastien Lebon
AU - Lucie Sedlackova
AU - Amanda Nagy
AU - Florian S. Eichler
AU - Chaya N. Murali
AU - Vincenzo Nigro
AU - Farah Alnoor Ladha
AU - Mark S. Ledoux
AU - Silvia Pelle
AU - Giulia Prato
AU - Lino Nobili
AU - Luigi Chiriatti
AU - Cecilia Mancini
AU - Giuseppe Zampino
AU - Claudio Graziano
AU - Kristin Baranano
AU - Pauline Planté-Bordeneuve
AU - Roseline Caumes
AU - Barbora Lauerová
AU - Jana Haberlová
AU - Duccio Maria Cordelli
AU - Chiara Fiorillo
AU - Marco Tartaglia
AU - Rory James Tinker
AU - Caterina Garone
PY - 2026
DA - 2026/11/09
JO - Neurology: Genetics
DO - 10.1212/nxg.0000000000200447
UR - https://doi.org/10.1212/nxg.0000000000200447
AB - Background and Objectives: UBTF encodes the upstream binding transcription factor (UBTF), a protein essential for rRNA synthesis. Dominantly acting pathogenic variants, either de novo or inherited, have been associated with a broad clinical childhood-onset neurodegenerative/neurodevelopmental spectrum whose genotype-phenotype correlation has not been accurately defined yet. This multicenter study aims to conduct a retrospective analysis of a large cohort of patients with pathogenic variants in the UBTF gene to refine diagnostic criteria and identify clinically relevant outcome measures for future trials. Methods: Clinical centers provided clinical, molecular, and neuroimaging data on patients carrying pathogenic or predicted pathogenic UBTF variants, consistent with the clinical phenotype. Data were collected using an human phenotype ontology–based standardized electronic case report form and included unreported cases or updated information on patients reported in the literature from January 2017 to December 2024. Results: A cohort of 49 patients (23 previously unreported) was included in the study. The disease typically presented at ≤3 years (89.6%) with neuroregression in 71.4% of cases, either in a child with preexisting neurodevelopmental delay (42.9%) or after previously normal psychomotor development (28.6%). Less frequently, neurodevelopmental delay occurred in isolation (26.5%). During disease progression, patients developed behavioral abnormalities (81.6%), movement disorders (78.3%), autonomic manifestations (50.0%), and epilepsy (34.7%). At the last follow-up (mean age 13 years and 6 months), only 2 patients were deceased (4.1%). The main neuroimaging findings included white matter hyperintensity (68.1%), cerebral (66.0%) and cerebellar (51.1%) atrophy, and thinning of the corpus callosum (38.3%). However, brain MRI findings were reported as normal in 21.3% of cases. We identified 7 novel UBTF variants (c.271G>C; c.349A>T; c.495C>A; c.517G>A; c.761A>G; c.1048-2A>G; and c.1625_1626+15del). Genotype-phenotype analysis led to the distinction of 2 allelic, clinically distinct disorders: a childhood-onset neurodegenerative disease due to gain-of-function variants, characterized by the triad of neuroregression, movement, and behavioral disorders, and a neurodevelopmental disorder with a milder clinical course associated with loss-of-function/hypomorphic variants. Discussion: The results from our deep-phenotyping analysis suggest the classification of UBTF-related disease into 2 main clinical syndromes impacting the natural history of the disease with a different degree of severity and complexity. This novel observation should be considered in the management and prognosis of patients and will be fundamental in the design of targeted therapies.
SN - 2376-7839
ER -